Contract analysis

I. EXECUTIVE SUMMARY This memorandum presents three distinct prosecution-reactivation scenarios for Optiwave Semiconductor Corp.'s ("OWS" or the "Company") twelve-application patent docket, which has remained substantially dormant since August 11, 2023, following Harborview Partners's ("Veltrano" or the "Sponsor") implementation of the Project Lighthouse discretionary spending freeze. The purpose of this memorandum i

II. BACKGROUND A. Engagement History Calderwood & Harkness LLP was engaged by Optiwave Semiconductor Corp. on or about February 10, 2022, when Marcus Whitfield, in his capacity as General Counsel, executed the engagement letter for patent prosecution services. The engagement was formally opened under C&H Matter No. 1014-00005 on February 14, 2022. The original scope of the engagement encompassed the patent prosecutio

III. CURRENT DOCKET STATUS SUMMARY A. Overview of the 12-Application Family The OWS patent docket under C&H's management consists of twelve pending applications organized into three sub-families. All twelve applications ultimately claim priority to U.S. Provisional Application No. 63/297,841, filed January 10, 2022. The three sub-families correspond to three distinct but interrelated technology areas within OWS's nex

IV. CRITICAL DEADLINE TRIAGE — RANKED BY URGENCY The following section organizes the pending deadlines in the OWS docket by urgency and consequence, using a three-tier traffic-light classification system. This classification is consistent with the companion Docket Status & Deadline Triage Memorandum being delivered contemporaneously. Priority 1 — RED: Imminent and Irrevocable These deadlines are approaching within th

V. SCENARIO 1: FULL REACTIVATION OF ALL 12 APPLICATIONS A. Scope Under Scenario 1, Calderwood & Harkness would resume active prosecution of all twelve pending applications across all three sub-families. This represents a complete reactivation of the docket to its pre-freeze posture, with prosecution activity proceeding on all U.S., European, and Japanese applications, as well as the remaining PCT national-phase entry

1. Full Portfolio Preservation. Scenario 1 preserves the entire twelve-application patent portfolio and its estimated $12.2 million value (per the Graystone April 28, 2023 valuation). No applications are abandoned, and no jurisdictional coverage is forfeited.

2. Complete Lender Covenant Compliance. Active prosecution of all pending applications ensures full compliance with Section 5.15 of the Meridian Credit Facility, eliminating the risk of a covenant default and potential acceleration of the $32.5 million outstanding balance.

3. Maximum Defensive Position Against Pinnacle Optics. Prosecution across all sub-families and all jurisdictions maximizes OWS's ability to assert a comprehensive patent portfolio against Pinnacle in the event of an infringement dispute, cross-licensing negotiation, or portfolio-level enforcement campaign.

4. Full Flexibility for Future Monetization. A complete, actively prosecuted portfolio preserves maximum flexibility for future licensing, cross-licensing, portfolio sale, or other monetization strategies. This is particularly relevant in the context of a potential future exit by Veltrano, where portfolio value would be a significant component of enterprise valuation.

5. International Protection. Full reactivation preserves patent protection in Europe, Japan, and potentially China and South Korea — jurisdictions that are critical to OWS's global customer base and competitive position. E. Disadvantages

1. Highest Total Cost. At $220,000–$295,000, Scenario 1 represents the most expensive path forward and may be incompatible with continued Project Lighthouse budget constraints absent a material revision to the spending cap.

2. Includes Lower-Priority Applications. Scenario 1 allocates resources to the Sub-Family C applications (packaging and thermal management), which, while commercially relevant, have less immediate strategic importance than the core modulator (Sub-Family A) and electrode process (Sub-Family B) applications. The incremental cost of prosecuting the C-family applications may not be justified under current budget constrai

3. Requires Additional Strategic Input on National-Phase Entries. The PCT national-phase entry decisions for A4 and A5 require input from OWS's commercial team regarding the relevance of additional jurisdictions (China, South Korea, etc.) to the Company's go-to-market strategy. This analysis has not yet been conducted and would add complexity and timeline to the reactivation process.

4. Exceeds Project Lighthouse Cap. The quarterly run-rate of $30,800–$40,800 substantially exceeds the $25,000/quarter cap, requiring either a revision to the cap or a multi-quarter exception from Veltrano.

VI. SCENARIO 2: SELECTIVE PROSECUTION OF HIGHEST-VALUE APPLICATIONS (RECOMMENDED) A. Scope Under Scenario 2, Calderwood & Harkness would concentrate prosecution resources on the four applications with the highest strategic value and/or the most imminent deadlines: A1, A3, B1, and B3, plus the B2 divisional that will follow from the B1 restriction election. All remaining applications would be placed on a monitoring-on

1. Concentrates Resources on Highest-Value Applications. Scenario 2 prioritizes the four applications that are most critical to OWS's defensive patent position against Pinnacle Optics and its manufacturing-process IP protection. The selected applications — A1, A3, B1, and B3 — together represent the core of OWS's patent strategy and the most commercially significant claim scope in the docket.

2. Cost-Effective. At $70,000–$107,000, Scenario 2 represents approximately 35–40% of the cost of full reactivation. The quarterly run-rate is achievable within or near the Project Lighthouse constraints, potentially with modest, time-limited exceptions for concentrated deadline quarters.

3. Preserves Core Portfolio Value. While not all twelve applications are actively prosecuted, the four selected applications and the B2 divisional together capture the most strategically valuable elements of the portfolio. The applications placed on hold remain pending and can be reactivated in subsequent budget cycles without loss of rights, provided their respective deadlines are managed.

4. Substantially Reduces Lender-Covenant-Default Risk. Active prosecution of the four most significant applications — including the foundational U.S. applications (A1 and B1) and the European protection (B3) — substantially mitigates the risk that Meridian National Bank could successfully assert a covenant default under Section 5.15. While the covenant language is broad ("all pending patent applications"), the argume

5. Maintains European Protection. By including B3 in the selected applications, Scenario 2 preserves European patent coverage for the electrode fabrication process — an important consideration given OWS's European customer relationships and competitive landscape. E. Disadvantages

1. Defers PCT National-Phase Entry Decisions. Under Scenario 2, the A4 and A5 national-phase entry decisions are deferred. If the July 9, 2025 thirty-month deadline passes without action, the opportunity to enter additional jurisdictions (China, South Korea, and any others) is permanently and irreversibly lost. This is a significant strategic concession, particularly given the growing importance of the Chinese optica

2. Sub-Family C Applications Unaddressed. The packaging and thermal management applications (C1, C2, C3) are not actively prosecuted under Scenario 2. While these applications are not currently facing imminent deadlines, they address technology areas that may become increasingly important as OWS's product line evolves and as the data-center industry moves toward co-packaged optics architectures. Deferring prosecution

3. Japanese Examination Requests Deferred. The B4 and C3 JPO examination requests (deadline January 9, 2026) are deferred to a subsequent budget cycle. While this is manageable given the longer timeline, it means that Japanese patent protection for both the electrode process and packaging technologies will be delayed, and the January 9, 2026 deadline will need to be addressed within approximately twelve months of rea

4. Potential Residual Lender-Covenant Exposure. Although Scenario 2 substantially mitigates the covenant-default risk, a conservative reading of the Meridian Credit Facility's Section 5.15 language — which requires OWS to "timely prosecut[e] all pending patent applications" — could support an argument that failure to actively prosecute every pending application constitutes a technical default. This argument is analyz

1. By January 31, 2025: Authorization for Phase 1 (A1 Office Action response). This authorization must be issued no later than January 31, 2025, to allow the prosecution team adequate preparation time before the March 9, 2025 absolute deadline. The response requires 40–55 hours of attorney work; assuming authorization by late January, the team would have approximately five to six weeks of working time. The incomplete

2. By March 15, 2025: Decision on Phase 2 elements — specifically, authorization for the B1 Restriction Requirement response, the B3 EPO EESR response (requiring coordination with Breitenfeld & Vogt), and the commencement of B2 divisional preparation. Authorizing Phase 2 by March 15 provides approximately five weeks of lead time before the April 21, 2025 B1 deadline and two months before the May 17, 2025 B3 deadline.

3. By June 1, 2025: Decision on A4/A5 national-phase entry strategy. Although Scenario 2 as presented does not include national-phase entries in additional jurisdictions, the July 9, 2025 deadline for A4 and A5 creates a decision point that must be addressed. C&H recommends that OWS and Veltrano evaluate, by June 1, 2025 at the latest, whether entering any additional national phases (China, South Korea) is warranted

4. By November 2025: Decision on B4 and C3 JPO examination requests. The January 9, 2026 deadline provides adequate lead time for this decision, but it should not be deferred beyond November 2025 to allow for coordination with Nakashima & Togawa and preparation of the necessary filings.

VII. SCENARIO 3: MINIMUM DEADLINE PRESERVATION A. Scope Scenario 3 represents the narrowest possible reactivation approach. Under this scenario, Calderwood & Harkness would address only the two most imminent, irrevocable deadlines in the docket: the A1 Office Action response (March 9, 2025) and the B1 Restriction Requirement response (April 21, 2025). No other applications would receive affirmative prosecution activi